"We create real world evidence data for the best possible treatment": Harald Schnidar, CEO of SCARLETRED, talks at AUTOMA+ 2025

Author

Hannah Felsberger

Speaking at AUTOMA+ 2025, SCARLETRED CEO Dr. Harald Schnidar shows how SCARLETRED®Vision, a CE-certified platform, transforms dermatology with remote, clinically validated, AI-powered skin assessments.

Harald Schnidar, CEO, Founder and President of SCARLETRED Holding GmbH, has introduced SCARLETRED®Vision at AUTOMA+ 2025 – the AI-powered MedTech solution addressing one of the biggest challenges in dermatology and pharmaceutical development: subjectivity of skin assessment.

In an exclusive interview at AUTOMA+ 2025, our CEO explains how SCARLETRED®Vision revolutionizes skin disease documentation, quantification and treatment evaluation, making dermatological imaging more precise, scalable, and effective across healthcare, clinical research, and industry applications.

“We are transferring AI from clinical setting to the home couch” is only the beginning. SCARLETRED®Vision also includes its clinically validated AI agent ARORA®AI. The agent allows SCARLETRED®Vision to create real-world evidence data which helps pharma companies, cosmetics, hospitals and clinical research partners to assess drug and treatment effects. “Thereby, we bring the best possible treatment to the patient”, says Dr. Schnidar in his interview.

The interview’s key points are:

Introduction to SCARLETRED®Vision:
Dr. Harald Schnidar explains the company’s AI-driven solution designed to improve objectivity and standardization on skin imaging, addressing limitations in traditional visual assessments.
‍
AI and Medical Technology – How does it work?
The system uses advanced Artificial Intelligence to analyze skin conditions, quantify visual changes, and support clinical decision-making in dermatology.
‍
Applications Across Skin Diseases – Why is it important?
SCARLETRED®Vision can monitor and assess a wide range of dermatological conditions and treatment responses, providing useful insights into clinical practice and research.
‍
Standardized Imaging Benefits:
‍The technology enables reproducible and regulatory-ready imaging that improves data quality and helps drive better outcomes in medical studies and patient care.
‍‍
Mobile and Scalable Platform:
SCARLETRED®Vision works through a mobile platform, allowing convenient remote assessments, broader access, and scalability for clinical, pharmaceutical, and cosmetic use cases.